MP
STLN

Mangrove Partners’s Starling Oncology STLN Stock Holding History

Mangrove Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,581
Closed -$109K – 589
2025
Q4 		$109K Buy
+30,581
New +$113K 0.01% 349

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $413M AUM 109.83% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mangrove Partners's STLN Position: Q1 2026 in Review

Mangrove Partners sold out of Starling Oncology (STLN) in Q1 2026, closing a stake of 30,581 shares — an estimated $109K sold.

Mangrove Partners first reported a position in STLN in Q4 2025 and held it in 1 quarter. The position peaked at $109K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Mangrove Partners reported no remaining Starling Oncology position as of Q1 2026 after selling out during the quarter.
  • Mangrove Partners sold 30,581 Starling Oncology shares in Q1 2026, an estimated $109K.
  • Mangrove Partners first reported a position in Starling Oncology in Q4 2025 and held it in 1 quarter.
  • Mangrove Partners's Starling Oncology position peaked at $109K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.